Try Alerts Free   |   Login
Health Care › Pharmaceutical Preparations

PDS Biotechnology (PDSB) Financials and Smart Investor 13F Alerts

See how revenue, income, cash flow, and balance sheet financials have changed over 19 quarters since 2016. Compare with PDSB stock chart to see long term trends.

PDSB stock compared to

PDSB Income Statement

Research & Development Expense:2060815
Total Operating Expenses:3907029
Operating Income:-3907029
Income Taxes:null
Net Income:-3905822
Earnings Per Share, Basic:-0.21
Shares Outstanding, Basic Avg:22261619

PDSB Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:null
Net Cash from Operations:-1252060
Net Cash from Financing Activities:17786500
Net Cash from Investing Activities:0
Net Change in Cash & Equivalents:16534440

PDSB Balance Sheet

Cash and Cash Equivalents:33468935
Total Current Assets:33842330
Property, Plant & Equipment, Net:9345
Total Assets:34445255
Accounts Payable:1559591
Total Short-Term Liabilities:2898604
Total Liabilities:null

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Renaissance Technologies LLC
783,857 sh
161,185 sh
26%
$1,826
$574
Vanguard Group Inc
583,826 sh
569,077 sh
3858%
$1,360
$1,330
Sabby Management, LLC
419,836 sh
419,836 sh
NEW
$978
$978
Blackrock Inc.
104,415 sh
90,002 sh
624%
$244
$215
Amussen Hunsaker Associates LLC
13,192 sh
 
$31
Northern Trust Corp
12,863 sh
-49 sh
0%
$30
$4
Virtu Financial LLC
10,086 sh
10,086 sh
NEW
$24
$24
Morgan Stanley
6,100 sh
6,100 sh
NEW
$14
$14
Bank Of America Corp /De/
15 sh
 
$0
Amussen Hunsaker Associates LLC
0 sh
-13,192 sh
-100%
$0
-$27
Tru Independence LLC
0 sh
-500 sh
-100%
$0
-$1
Proequities, Inc.
0 sh
 
$0

Data imported from PDS Biotechnology Corp SEC filings. Check original filings before making any investment decision.